文献速递临床微生物分子诊断质量管理与危急值

简化吡嗪酰胺酶试验用于结核分枝杆菌吡嗪酰胺药敏检测

A simplified pyrazinamidase test for Mycobacterium tuberculosis pyrazinamide antimicrobial susceptibility testing.
PubMed 文献 · J Clin Microbiol · 2024-11-18

研究开发了一种简化显色吡嗪酰胺酶(PZase)试验,用于结核分枝杆菌复合群(MTBC)的吡嗪酰胺(PZA)药敏检测。在106株训练集分离株中,PZase试验与pncA基因Sanger测序的符合率为100.0%,MGIT-PZA药敏试验为99.1%。在10家临床实验室对1,793株临床分离株验证,排除重复及未表征耐药突变株后,PZA耐药率为2.6%(43/1,627),其中牛分枝杆菌占1.3%(21/1,627),各实验室准确度为98.5%-100.0%。

要点

  • 简化PZase试验与pncA测序和MGIT-PZA药敏试验高度一致,适合整合入常规一线药敏。
  • 训练集中32.1%(34/106)菌株携带pncA突变,包括一株沉默突变S65S。
  • 验证中10家实验室PZase试验准确度为98.5%-100.0%,kappa值0.851-1.000。

核心结论

  • 简化PZase试验与pncA基因Sanger测序及MGIT-PZA药敏试验显示高度一致性,可简便整合入常规一线药敏检测。

研究设计与样本

  • 在结核参考实验室使用具有不同耐药谱的MTBC训练集分离株开发简化显色PZase试验,并在10家临床实验室用连续BACTEC MGIT 960培养阳性菌株进行验证。
  • 以pncA基因Sanger测序结果为参考,并与MGIT-PZA药敏试验比较;使用专利性内部实时PCR对牛分枝杆菌进行鉴别诊断。

主要发现

  • 106株训练分离株中,PZase试验与Sanger测序符合率为100.0%,MGIT-PZA药敏试验符合率为99.1%。
  • 训练集中32.1%(34/106)分离株携带pncA突变,包括一株沉默突变S65S。
  • 验证共测试1,793株临床分离株,包括150株来自同一病例标本的重复分离株和16株携带未表征耐药相关突变的分离株。
  • 排除重复和未表征耐药突变分离株后,鉴定PZA耐药分离株占2.6%(43/1,627),其中牛分枝杆菌占1.3%(21/1,627)。
  • kappa值为0.851-1.000,10家实验室PZase试验准确度为98.5%-100.0%。

关键数值与推荐

  • 训练集PZase试验与Sanger测序符合率100.0%,MGIT-PZA药敏试验符合率99.1%。
  • 验证集PZA耐药率2.6%(43/1,627),牛分枝杆菌占1.3%(21/1,627)。
  • PZase试验与参考方法kappa值0.851-1.000,10家实验室准确度98.5%-100.0%。

临床怎么用

  • 可将简化PZase试验整合入常规一线药敏检测,作为PZA耐药筛查的简便方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Pyrazinamide (PZA) is an important first-line drug for tuberculosis (TB) treatment by eradicating the persisting Mycobacterium tuberculosis complex (MTBC). Due to cost and technical challenges, end TB strategies are hampered by the lack of a simple and reliable culture-based PZA antimicrobial susceptibility testing (AST) for routine use. We initially developed a simplified chromogenic pyrazinamidase (PZase) test in the TB reference laboratory using a training set MTBC isolates with various drug-resistant profiles, and validated its performance using consecutive BACTEC MGIT 960 (MGIT)-culture-positive culture in 10 clinical laboratories. The pncA gene Sanger sequencing results were used as the reference, and compared to the MGIT-PZA AST. Differential diagnosis of Mycobacterium bovis was conducted using patented in-house real-time PCR. Of the 106 training isolates, the PZase test and MGIT-PZA AST showed 100.0% and 99.1% concordance as compared to Sanger sequencing, respectively. We found 32.1% (34/106) isolates harbored pncA mutations, including one isolate with silent mutation S65S. For validation, 1,793 clinical isolates were tested including 150 duplicate isolates from specimens of the same cases and 16 isolates with uncharacterized drug resistance (UDR)-associated mutations. Excluding duplicated and UDR isolates, we identified 2.6% (43/1,627) PZA-resistant isolates, including 1.3% (21/1,627) M. bovis isolates. The kappa values were 0.851-1.000. In addition, the accuracy of the PZase test conducted by 10 laboratories was 98.5%-100.0%. Our simplified PZase test demonstrated high concordance with Sanger sequencing and MGIT-PZA AST. Integrating the PZase test into routine first-line AST is effortless and represents an improvement in laboratory services for ending TB. IMPORTANCE: We developed and validated a simple pyrazinamidase (PZase) test for pyrazinamide (PZA) antimicrobial susceptibility testing (AST). Our results demonstrated that the PZase test had high agreement with the pncA gene sequencing and MGIT-PZA AST. Integrating PZase test into routine AST is effortless and represents an improvement in laboratory services for ending TB.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Chan H-H, Wang Y-C, Jou R, et al. A simplified pyrazinamidase test for Mycobacterium tuberculosis pyrazinamide antimicrobial susceptibility testing. J Clin Microbiol. 2024. PMID: 39555932. doi:10.1128/jcm.01227-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。